Millennium Management’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-606,513
| Closed | -$20.3M | – | 6356 |
|
|
2026
Q1 | $20.3M | Sell |
606,513
-629,808
| -51% | -$24.7M | 0.01% | 1536 |
|
|
2025
Q4 | $57.2M | Buy |
1,236,321
+256,495
| +26% | +$14.1M | 0.02% | 721 |
|
|
2025
Q3 | $66.2M | Buy |
979,826
+346,105
| +55% | +$25.7M | 0.03% | 677 |
|
|
2025
Q2 | $53.1M | Sell |
633,721
-45,570
| -7% | -$3.41M | 0.03% | 776 |
|
|
2025
Q1 | $48.5M | Buy |
679,291
+202,490
| +42% | +$9.86M | 0.03% | 790 |
|
|
2024
Q4 | $21.4M | Buy |
476,801
+221,912
| +87% | +$11.5M | 0.01% | 1472 |
|
|
2024
Q3 | $12.9M | Sell |
254,889
-203,631
| -44% | -$9.75M | 0.01% | 1965 |
|
|
2024
Q2 | $18.7M | Buy |
458,520
+366,295
| +397% | +$15.5M | 0.01% | 1563 |
|
|
2024
Q1 | $3.95M | Buy |
92,225
+78,542
| +574% | +$3.55M | ﹤0.01% | 3115 |
|
|
2023
Q4 | $551K | Sell |
13,683
-41,773
| -75% | -$1.19M | ﹤0.01% | 4585 |
|
|
2023
Q3 | $1.64M | Buy |
+55,456
| New | +$336K | ﹤0.01% | 3750 |
|
|
2023
Q1 | – | Sell |
-45,876
| Closed | -$91K | – | 6819 |
|
|
2022
Q4 | $91K | Buy |
+45,876
| New | +$57.1K | ﹤0.01% | 5611 |
|
|
2022
Q3 | – | Sell |
-3,088
| Closed | -$9K | – | 7452 |
|
|
2022
Q2 | $9K | Buy |
+3,088
| New | +$8.55K | ﹤0.01% | 6694 |
|
|
2021
Q3 | – | Sell |
-12,998
| Closed | -$222K | – | 7214 |
|
|
2021
Q2 | $222K | Buy |
+12,998
| New | +$220K | ﹤0.01% | 5950 |
|
|
2020
Q4 | – | Sell |
-4,074
| Closed | -$153 | – | 5552 |
|
|
2020
Q3 | $153 | Buy |
4,074
+1,340
| +49% | +$39.2K | ﹤0.01% | 4140 |
|
|
2020
Q2 | $91K | Sell |
2,734
-6,280
| -70% | -$272K | ﹤0.01% | 3991 |
|
|
2020
Q1 | $322K | Buy |
+9,014
| New | +$384K | ﹤0.01% | 3139 |
|
Millennium Management's SLNO Position: Q2 2026 in Review
Millennium Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 606,513 shares — an estimated $20.3M sold.
Millennium Management first reported a position in SLNO in Q1 2020 and held it in 17 quarters. The position peaked at $66.2M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Millennium Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Millennium Management sold 606,513 Soleno Therapeutics shares in Q2 2026, an estimated $20.3M.
- Millennium Management first reported a position in Soleno Therapeutics in Q1 2020 and held it in 17 quarters.
- Millennium Management's Soleno Therapeutics position peaked at $66.2M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.